Phase I/II Trial of AG-221 in Advanced Hematologic Cancer


Phase I/II Trial of AG-221 in Advanced Hematologic Cancer
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Stein EM et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: Results of a Phase 1/2 trial. Proc ASH 2015;Abstract 323.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.